Monalizumab (** Generic (investigational) **)

Immunotherapy

EU Experimental ES Not available 1 Clinical Trials

Description

Monalizumab is under investigation for use in colorectal cancer as a potential therapy, particularly in combination with other immunotherapies or targeted agents. Its efficacy and safety are currently being evaluated in clinical trials for patients who have progressed on standard therapies.

Mechanism of Action

Monalizumab is a bispecific antibody that targets both NKG2D and DLL4, enhancing the immune response against tumor cells expressing NKG2D ligands while inhibiting angiogenesis through DLL4 signaling.

Side Effects

Fatigue; nausea; diarrhea; anemia; thrombocytopenia; neutropenia

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT02671435 Phase 1
Active, not recruiting
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
United States, Australia, Belgium, Canada, France, Hungary, Italy, New Zealand,

Quick Info

Brand Name** Generic (investigational) **
CategoryImmunotherapy
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Bevacizumab
Immunotherapy
512 trials
Cetuximab
Immunotherapy
364 trials
Pembrolizumab
Immunotherapy
196 trials
Panitumumab
Immunotherapy
126 trials
Nivolumab
Immunotherapy
116 trials
Tislelizumab
Immunotherapy
62 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.